Abstract
The frontline therapy R-CHOP for patients with diffuse large B-cell lymphoma (DLBCL) has remained unchanged for two decades despite numerous Phase III......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
